Evidence map›Paper›PMID 36176836›Full record

ArticleCureus2022

Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib.

Austin R Swisher, Mark J Landau, Allison B Davila, Armando A Davila, Caryn Zagaynov, Christopher A Bobbitt, Darren S Leong, Alexander Y Chang, Walter T Chang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Austin R SwisherDepartment of Surgery, University of California Riverside School of Medicine, Riverside, USA.
Mark J LandauDepartment of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
Allison B DavilaDepartment of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
Armando A DavilaDepartment of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
Caryn ZagaynovDepartment of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
Christopher A BobbittDepartment of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
Darren S LeongDepartment of Plastic Surgery, Kaiser Permanente Fontana Medical Center, Fontana, USA.
Alexander Y ChangDepartment of Plastic Surgery, Kaiser Permanente Fontana Medical Center, Fontana, USA.
Walter T ChangDepartment of Plastic Surgery, Kaiser Permanente Fontana Medical Center, Fontana, USA.
Loma Linda University · USKaiser Permanente Fontana Medical Center · USLoma Linda University Medical Center · USUniversity of California, Riverside · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is a common skin malignancy that can present reconstructive challenges in patients with locally advanced diseases of the extremities. This article highlights three cases of locally advanced BCC of the extremities managed with vismodegib (Erivedge, Genentech). Vismodegib is a sonic hedgehog pathway (Shh) inhibitor approved by the FDA for use in metastatic or recurrent BCC. All three patients in our case series demonstrated significant clinical responses with reductions in tumor size which obviated the need for complex reconstructive surgery or amputation.

Indexed as

basal cell carcinomaneoadjuvantsonic hedgehogupper extremityvismodegib

Identifiers

PMID36176836
PMCPMC9512297
OpenAlexW4293359965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.